Kidney Transplant Clinical Trial
Official title:
Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer
Hyperkalemia (high potassium in blood) is a common condition found in kidney transplant patients. Risk factors include poor kidney function and exposure to various drugs. Regardless of the causes, current treatment options are limited. Previously, the only available potassium binder for lowering potassium in the blood is sodium polystyrene sulfonate, which has unknown drug interaction profile with transplant medications. Patiromer is a newly approved potassium binder indicated for the treatment of hyperkalemia. Kidney transplant patients with hyperkalemia may benefit from patiromer. However, the interaction of patiromer and transplant medications has not been studied. The goal of this study is to look into the drug interactions between patiromer and transplant medications.
This is an open-label single center pharmacokinetic study of kidney transplant recipients
with hyperkalemia receiving tacrolimus and MMF-based immunosuppression.
Subjects will be screened for inclusion and exclusion criteria during the screening visit.
There will be 2 study visits (visit 0 and visit 1) for each subject after successful
screening. Visit 0 occurs within 14 days (± 3 days) after screening. Visit 1 occurs at 7 days
(± 3 days) after visit 0. There will be 3 clinical visits (standard of care) after visit 1. A
total of 6 visits are anticipated for this study.
Standard diet for lunch and dinner will be provided to subjects during visit 0 and visit 1.
Meals provided will be monitored in relationship to C0 and C12.
During screening visit, blood tests for baseline BMP, aldosterone, magnesium, tacrolimus,
DSA, and MMF will be obtained. If applicable, concomitant fludrocortiosone will be stopped
prior to screening.
During visit 0, tacrolimus levels will be drawn immediately before (0 hr) and at 8 intervals
after dosing (1,2,3,4,5,6,9,12 hrs). MMF levels will be drawn immediately before (0 hr) and
at 9 intervals after dosing (1,2,3,4,5,6,7,9,12 hrs). Basic metabolic profile and serum
magnesium levels will be drawn immediately before tacrolimus dosing. Oral MMF and tacrolimus
will be dosed at 8am ± 1hr.
Enrollment is defined as the first day when subject receives patiromer treatment. Patiromer
(8.4 grams) will be taken daily at 3 hours after oral tacrolimus and MMF dosing by subjects
commencing 3 days (± 1 day) prior to visit 1. No tacrolimus or MMF dosing changes are allowed
between visit 0 and 1. The addition of new concomitant drugs causing interactions with
tacrolimus and MMF are prohibited between visit 0 and 1.
During visit 1, subjects will follow the same protocol of blood draws as visit 0. Tacrolimus
levels will be drawn immediately before (0 hr) and at 8 intervals after tacrolimus dosing
(1,2,3,4,5,6,9,12 hrs). MMF levels will be drawn immediately before (0 hr) and at 9 intervals
after MMF dosing (1,2,3,4,5,6,7,9,12 hrs). Basic metabolic profile and serum magnesium levels
will be drawn immediately before tacrolimus dosing. Patiromer at 8.4 grams will be given 3
hrs after tacrolimus and MMF dosing. Oral MMF and tacrolimus will be dosed at 8am ± 1hr.
All subjects will followup for clinical visits (2-4) with the PI or their transplant
nephrologists after visit 1 according to schedule (see appendix for study visit events).
Subjects will complete study by 30 days (± 7 days) after visit 0. Adjustment of patiromer
dosing is at the discretion of PIs after visit 2. After completion of study visits, subjects
will continue to follow with transplant clinic monthly for 2 months or sooner if clinically
indicated per the discretion of the treating transplant nephrologist. After 2 months, clinic
visits will be conducted per routine clinic schedule.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04087720 -
Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant
|
Phase 4 | |
| Completed |
NCT03749356 -
Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients
|
Phase 4 | |
| Withdrawn |
NCT05811468 -
Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
|
||
| Completed |
NCT03527238 -
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
|
Phase 2 | |
| Completed |
NCT00498576 -
Melatonin and Adiponectin in Hypertensive Kidney Transplant
|
N/A | |
| Completed |
NCT00642655 -
Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT00374400 -
The Paired Donation Consortium Paired Donation Program
|
N/A | |
| Completed |
NCT01710033 -
A Study Of CP-690,550 In Stable Kidney Transplant Patients
|
Phase 1 | |
| Completed |
NCT00205257 -
Prediction of Acute Rejection in Renal Transplant
|
Phase 1 | |
| Completed |
NCT02711826 -
Treg Therapy in Subclinical Inflammation in Kidney Transplantation
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03978494 -
Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.
|
Phase 1 | |
| Completed |
NCT03837522 -
Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies
|
N/A | |
| Not yet recruiting |
NCT06025240 -
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
|
||
| Completed |
NCT05029310 -
Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients
|
Phase 4 | |
| Completed |
NCT03644485 -
Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients
|
Phase 4 | |
| Active, not recruiting |
NCT02409901 -
Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients
|
N/A | |
| Completed |
NCT01047410 -
ACtive Care After Transplantation, the ACT Study
|
N/A | |
| Completed |
NCT00940940 -
Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation
|
Phase 4 | |
| Completed |
NCT00217126 -
The Study of Long-term Deterioration of Kidney Transplants.
|
Phase 4 | |
| Completed |
NCT00270712 -
A Study of Factors That Affect Long-Term Kidney Transplant Function
|